The objective of this patient registry is to collect data on the safety of Berinert® in normal clinical practice in the United States. The patient registry will be maintained for a period of at least 3 years. The duration of individual patient participation will vary and is determined by the frequency of hereditary angioedema (HAE) attacks and the patient's need for Berinert® treatment.
Study Type
OBSERVATIONAL
Enrollment
318
Berinert® is marketed as a lyophilized concentrate available in a single-use vial to be reconstituted with sterile water before administration as described in the prescribing information.
Incidence of thrombotic and thrombo-embolic events
Time frame: Within 30 days of treatment with Berinert®
Occurrence of suspected viral transmission
Time frame: Duration of the study, at least 3 years
Use of concomitant medications and plasma products
Time frame: Duration of the study, at least 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
United States, Arizona
Scottsdale, Arizona, United States
United States, California
Granada Hills, California, United States
United States, California
Los Angeles, California, United States
United States, California
Redding, California, United States
United States, California
San Diego, California, United States
United States, Georgia
Atlanta, Georgia, United States
United States, Idaho
Idaho Falls, Idaho, United States
United States, Louisiana
New Orleans, Louisiana, United States
United States, Maryland
Chevy Chase, Maryland, United States
United States, Maryland
Columbia, Maryland, United States
...and 30 more locations